We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Provectus Biopharmaceuticals Inc (PVCT) USD0.001

Sell:$0.12 Buy:$0.12 Change: $0.003835 (3.20%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$0.12
Buy:$0.12
Change: $0.003835 (3.20%)
Deal now Deal for just £11.95 per trade in a Fund and Share Account
Deal now
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$0.12
Buy:$0.12
Change: $0.003835 (3.20%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing immunotherapy medicines for different diseases that are based on a class of synthetic small-molecule immuno-catalysts called halogenated xanthenes (HXs). The Company’s lead molecule is named rose bengal sodium (RBS). The Company’s small molecule HX medical science platform comprises a range of different drug product candidates and preclinical pharmaceutical-grade RBS formulations using different concentrations and delivered by different routes of administration specific to each disease area and/or indication. The Company’s HX medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; in vivo proof-of-concept drug discovery programs in oncology, hematology, wound healing, and animal health, and in vitro drug discovery programs in infectious diseases and tissue regeneration and repair.

Contact details

Address:
800 S. Gay Street, Suite 1610
KNOXVILLE
37929
United States
Telephone:
+1 (865) 7694011
Website:
https://www.provectusbio.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
PVCT
ISIN:
US74373P1084
Market cap:
$50.29 million
Shares in issue:
420.28 million
Sector:
Pharmaceuticals
Exchange:
Off Exchange
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Edward Pershing
    Chairman of the Board, Chief Executive Officer
  • Dominic Rodrigues
    President, Vice Chairman of the Board, Principal Executive Officer
  • Heather Raines
    Chief Financial Officer
  • Eric Wachter
    Chief Technology Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.